Joseph E Bugaj

Author PubWeight™ 7.69^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents.	J Med Chem	2002	1.45
2	Novel approach in radionuclide tumor therapy: dose enhancement by high Z-element contrast agents.	Cancer Biother Radiopharm	2006	1.42
3	18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.	Clin Cancer Res	2011	1.13
4	DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.	Bioconjug Chem	2002	1.07
5	Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.	J Nucl Med	2002	0.99
6	Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.	J Med Chem	2003	0.83
7	Dose enhancement through combining internalizing radiation and contrast media.	Cancer Biother Radiopharm	2006	0.78